More Spanish Biotechs To Benefit From Ysios Backing

Latest Fund Closes at €216m

Spain now enjoys a reasonable level of venture capital to help translate its scientific excellence into budding biotechs and the country's major life sciences backer Ysios is looking to unearth more jewels there, as well as in the rest of Europe and North America.

Ysios
Ysios partners (L-R) Raúl Martín-Ruiz, Cristina Garmendia, Julia Salaverria, Karen Wagner, Joël Jean-Mairet, Paula Olazábal

Spain's biotech sector has come a long way in the last decade or so, with its strong science capabilities now augmented by significant investment, much of which has come from Ysios, the country's largest life sciences venture capital firm, which has closed its third fund at €216m ($260m).

Ysios BioFund 3 (YBF 3), the group's largest to date, is targeting seed/early-stage and development-stage biotechs, with investment size per...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Sanofi’s Blueprint buy; AstraZeneca’s breast cancer resistance results at ASCO; BMS and BioNTech’s big bispecific deal; Kymera’s Dupixent in a pill; and Degron’s CEO on pipeline and strategy.

Chinese Biotech VC/PE Fundings Rise But Still Modest

 

LTZ Therapeutics and Beijing Sungen Biomedical are among the Chinese biotechs raising new funding, of around $40m each, based on their clinical assets with novel mechanisms of action. While fundings have risen, they remain moderate however.

Otsuka’s IgAN Data Top Some Vera Results, But To What End?

 
• By 

Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.